Neurocrine Biosciences | Stammkapital



Ordinary Share Capital Veränderung Datum
AbbVie USD 18M 0 2024-12
Acadia Pharmaceuticals USD 16K 0 2024-12
Agios Pharmaceuticals USD 73K 0 2024-12
ALKERMES USD 1.77M 4K 2024-12
Alnylam Pharmaceuticals USD 1.29M 4K 2024-12
Amgen USD 33.53B 140M 2024-12
Biogen USD 100K 0 2024-12
BioMarin Pharmaceutical USD 191K 0 2024-12
Cytokinetics USD 118K 0 2024-12
Dynavax Technologies USD 125K 6K 2024-12
Exelixis USD 282K 4K 2025-01
Gilead Sciences USD 1000K 0 2024-12
Halozyme Therapeutics USD 123K 4K 2024-12
Incyte USD 193K 1000 2024-12
Intra Cellular Therapies USD 11K 0 2024-12
Ionis Pharmaceuticals USD 158K 0 2024-12
Neurocrine Biosciences USD 100K 0 2024-12
Pfizer USD 480M 0 2024-12
Prothena USD 538K 0 2024-12
Regeneron Pharmaceuticals USD 100K 2K 2024-09
Repligen USD 560K 1000 2024-09
Sarepta Therapeutics USD 10K 0 2024-12
Teva Pharmaceutical Industries USD 58M 0 2024-09
Ultragenyx Pharmaceutical USD 92K 0 2024-12
Vertex Pharmaceuticals USD 2.6M 0 2024-12



Neurocrine Biosciences Stammkapital - Diese Werte, historische Daten, Prognosen, Statistiken, Diagramme und ökonomische Kalender - Mar 2025.